Vireo Growth (VREOF) Goodwill & Intangibles (2020 - 2026)
Vireo Growth (VREOF) reported Goodwill & Intangibles of $202.5 million for Q1 2026, up 2531.74% on a YoY basis from $7.7 million in Q1 2025, and up 0.9% sequentially from $200.7 million in Q4 2025.
Vireo Growth (VREOF) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Goodwill & Intangibles data on file, last reported at $202.5 million in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles rose 2531.74% year-over-year to $202.5 million; the trailing twelve-month figure through Mar 2026 stood at $202.5 million (up 2531.74% YoY), and the FY2025 full-year result was $200.7 million, up 2440.51% from the prior year.
- Goodwill & Intangibles improved to $202.5 million in Q1 2026, from $200.7 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $202.5 million in Q1 2026 to a low of $7.7 million in Q1 2025.
- A 5-year average of $50.1 million and a median of $8.9 million in 2023 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles tumbled 30.25% in 2022 and soared 2531.74% in 2026, its largest moves.
- Tracing VREOF's Goodwill & Intangibles over 5 years: stood at $9.0 million in 2022, then fell by 0.65% to $8.9 million in 2023, then retreated by 11.26% to $7.9 million in 2024, then jumped by 2440.51% to $200.7 million in 2025, then grew by 0.9% to $202.5 million in 2026.
- Business Quant data shows VREOF's Goodwill & Intangibles at $202.5 million in Q1 2026, $200.7 million in Q4 2025, and $180.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202.50 Mn |
| Dec 31, 2025 | 200.70 Mn |
| Sep 30, 2025 | 180.47 Mn |
| Jun 30, 2025 | 151.85 Mn |
| Mar 31, 2025 | 7.69 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 8.10 Mn |
| Jun 30, 2024 | 8.31 Mn |
| Mar 31, 2024 | 8.51 Mn |
| Dec 31, 2023 | 8.90 Mn |
| Sep 30, 2023 | 8.94 Mn |
| Jun 30, 2023 | 8.05 Mn |
| Mar 31, 2023 | 8.80 Mn |
| Dec 31, 2022 | 8.96 Mn |
| Sep 30, 2022 | 11.89 Mn |
| Jun 30, 2022 | 9.96 Mn |
| Mar 31, 2022 | 10.13 Mn |
| Dec 31, 2021 | 10.37 Mn |
| Sep 30, 2021 | 5.61 Mn |
| Jun 30, 2021 | 6.32 Mn |